VBL Therapeutics

162 articles with VBL Therapeutics

• VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

  6/15/2021

  VBL Therapeutics provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec, for the treatment of platinum-resistant ovarian cancer.

• VBL Therapeutics Announces Addition of Progression Free Survival as a Second Primary Endpoint in OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

  6/3/2021

  Clinical trial amendment reported in an OVAL Clinical Trial in Progress poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

• VBL Therapeutics to Provide an Update on the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

  5/20/2021

  VBL Therapeutics (Nasdaq: VBLT) today announced that a poster providing an update on the OVAL Phase 3 registration enabling clinical trial of VB-111 in ovarian cancer will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

• VBL Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

  5/11/2021

  OVAL Phase 3 registration-enabling study investigating VB-111 in patients with platinum-resistant ovarian cancer remains on track in spite of COVID-19, with over 260 patients enrolled; next DSMC review expected 3Q21

• VBL Therapeutics to Report First Quarter Financial Results on May 11

  5/4/2021

  VBL Therapeutics will release its first quarter financial results for the period ended March 31, 2021 on Tuesday, May 11, 2021 before market open.

• Vascular Biogenics Ltd. Closes Public Offering of Ordinary Shares and Pre-Funded Warrants - Apr 14, 2021

  4/14/2021

  Vascular Biogenics Ltd., announced the closing of its underwritten public offering of 6,901,790 ordinary shares, and, to certain investors in lieu thereof, pre-funded warrants to purchase 8,050,000 ordinary shares in an underwritten public offering, at a price to the public of $1.90 per ordinary share and $1.89 per pre-funded warrant.

• Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants

  4/9/2021

  Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT), today announced the pricing of an underwritten public offering of 5,150,265 ordinary shares and, to certain investors in lieu thereof, pre-funded warrants to purchase 8,050,000 ordinary shares in an underwritten public offering, at a price to the public of $1.90 per ordinary share and $1.89 per pre-funded warrant

• Vascular Biogenics Ltd. Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

  4/8/2021

  Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT), today announced that it intends to offer and sell ordinary shares and, to certain investors in lieu thereof, pre-funded warrants to purchase ordinary shares in an underwritten public offering

• VBL Therapeutics to Host Virtual R&D Day on April 6

  3/30/2021

  VBL Therapeutics announced that it will host a virtual R&D Day for analysts and investors beginning at 10:00am ET on Tuesday, April 6, 2021.

• VBL Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

  3/25/2021

  Continued progress in OVAL Phase 3 registration enabling study investigating VB-111 in patients with platinum-resistant ovarian cancer; high CA-125 response rates (RR) of over 50% in the total evaluable patient population with more than200 patients enrolled to date.

• VBL Therapeutics to Report Fourth Quarter and Full Year Financial Results on March 25

  3/17/2021

  VBL Therapeutics (Nasdaq: VBLT) will release its fourth quarter and full year results for the period ended December 31, 2020 on Thursday, March 25, 2021 before market open. Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron, Chief Financial Officer, will host a conference call at 8:30am ET the same day to discuss the results and provide a corporate update.

• VBL Therapeutics to Participate at Upcoming Virtual Investor Conferences

  3/8/2021

  VBL Therapeutics (Nasdaq: VBLT) today announced the Company will participate in the following upcoming virtual investor conferences: H.C Wainwright Global Life Sciences Conference Tuesday, March 9, 2021 Presentation available on-demand beginning at 7:00 a.m. ET 33rd Annual Roth Conference

• VBL Therapeutics Announces Peer-reviewed Publication of Positive Results of Pre-specified Interim Analysis of OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

  3/4/2021

  VBL Therapeutics (Nasdaq: VBLT) today announced the online publication of positive results of the pre-specified interim analysis of the OVAL study, a Phase 3 registration enabling study of VB-111 (ofranergene obadenovec) in recurrent platinum-resistant ovarian cancer.

• VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma Multiforme

  3/1/2021

  VBL Therapeutics announced that patient dosing has been initiated in a Phase 2 clinical trial investigating ofranergene obadenovec for the treatment of recurrent glioblastoma multiforme.

• VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

  2/22/2021

  VBL Therapeutics (Nasdaq: VBLT) today announced the results of the independent Data Safety Monitoring Committee (DSMC) pre-planned review of the ongoing OVAL Phase 3 registration enabling study of VB-111 in recurrent ovarian cancer.

• VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients

  1/27/2021

  VBL Therapeutics (Nasdaq: VBLT) today announced the dosing of the first patient in a randomized controlled Phase 2 study of the Company’s proprietary investigational oral immune-modulator molecule, VB-201 for the treatment of COVID-19.

• VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLCAgreement extends current cash runway to Q1 2023

  1/15/2021

  VBL Therapeutics (Nasdaq: VBLT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications, today announced that it has entered into an Ordinary Share Purchase Agreement with Aspire Capital Fund, LLC. Proceeds from any sales of ordinary shares pursuant to the Purchase Agreement will be used for workin

• 

  Clinical Catch-Up: December 28, 2020-January 1, 2021

  1/4/2021

  It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.

• VBL Therapeutics Announces First Patient in Europe in the OVAL Trial

  12/29/2020

  Expands OVAL Phase 3 Potential Registration Study of VB-111 for the Treatment of Platinum-Resistant Ovarian Cancer into Europe 

• VBL Therapeutics Announces Insider Buying

  12/7/2020

  VBL Therapeutics announced that the Company's Chairman of the Board, Dr. Bennett Shapiro, the CEO, Prof. Dror Harats and additional Company board members and senior management, made open-market purchases of approximately 200K shares of VBLT, between November 24 and December 3, 2020.